NCT01694602View on ClinicalTrials.gov

Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II

CompletedOBSERVATIONAL
Enrollment

8

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Cachexia
Interventions
BIOLOGICAL

(non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)

Oral dose of 9.0 mg (50 μmol) TAU-METHYL-L-HISTIDINE (METHYL-D3), Cambridge Isotope Laboratory, Cambridge, Massachusetts.

Trial Locations (1)

77555-0361

University of Texas Medical Branch, Galveston

All Listed Sponsors
lead

The University of Texas Medical Branch, Galveston

OTHER

NCT01694602 - Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II | Biotech Hunter | Biotech Hunter